Public Health England

NHS

PHE publications gateway number: 2017177

PATIENT GROUP DIRECTION (PGD)

Administration of diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, *Haemophilus influenzae* type b and hepatitis B vaccine (DTaP/IPV/Hib/HepB) to individuals from 6 weeks (routinely 8 weeks) to under 10 years of age in accordance with the national immunisation programme.

This PGD is for the administration of diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, *Haemophilus influenzae* type b and hepatitis B vaccine (DTaP/IPV/Hib/HepB) by currently registered nurses or paramedics.

Reference no:	DTAP/IPV/Hib/HepB PGD
Version no:	v01.00
Valid from:	12 September 2017
Review date:	1 March 2019
Expiry date:	31 August 2019

Public Health England has developed this PGD template to facilitate the delivery of immunisations in the NHS in line with national recommendations.

Those using this PGD must ensure that it is organisationally authorised and signed in Section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)[1]. **THE PGD IS NOT LEGAL OR VALID WITHOUT SIGNED AUTHORISATION IN ACCORDANCE WITH HMR2012 SCHEDULE 16 Part 2.**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition authorising organisations must not alter section 3 'Characteristics of staff'. Only sections 2 and 7 can be amended.

Operation of this PGD is the responsibility of commissioners and service providers.

INDIVIDUAL PRACTITIONERS MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of PHE PGD templates for authorisation can be found from: https://www.gov.uk/government/collections/immunisation

Any concerns regarding the content of this PGD should be addressed to: immunisation@phe.gov.uk

[1] This includes any relevant amendments to legislation (eg 2013 No235, 2015 No.178 and 2015 No.323).

Change history

Version number	Change details	Date
V01.00	New PHE PGD template	03/07/2017

1. PGD template development

This PGD template has been developed by the following health professionals on behalf of Public Health England:

Developed by:	Name	Signature	Date
Pharmacist (Lead Author)	Elizabeth Graham Lead Pharmacist Immunisation Services, PHE		03/07/2017
Doctor	Mary Ramsay Consultant Epidemiologist and Head of Immunisation, Hepatitis & Blood Safety Department, PHE		03/07/2017
Registered Nurse (Chair of Expert Panel)	David Green Nurse Consultant – Immunisations, PHE		03/07/2017

This PGD template has been peer reviewed by the PHE Immunisations PGD Expert Panel in accordance with PHE PGD Policy. It has been ratified by PHE Medicines Management Group and PHE Quality and Clinical Governance Steering Group.

Expert Panel

Name	Designation
Ed Gardner	Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead
Jacqueline Lamberty	Lead Pharmacist Medicines Management Services, Public Health England
Vanessa MacGregor	Consultant in Communicable Disease Control, Public Health England, East Midlands Health Protection Team
Alison Mackenzie	Consultant in Public Health Medicine, Screening and Immunisation Lead, Public Health England / NHS England South (South West)
Sema Mandal	Medical Consultant Epidemiologist, Public Health England
Gill Marsh	Senior Screening and Immunisation Manager Public Health England / NHS England Lancashire and South Cumbria
Lesley McFarlane	Screening and Immunisation Co-ordinator (SIC) NHS England Leicestershire, Lincolnshire and Northamptonshire
Sally Millership	Consultant in Communicable Disease Control, Public Health England, East of England Health Protection Team
Matthew Olley	Immunisation Manager, Public Health England / NHS England London Region
Lisa Rees	Medicines Management Pharmacist, Bristol Clinical Commissioning Group
Tushar Shah	Pharmacy Advisor, NHS England London Region
Kelly Stoker	Senior Health Protection Nurse, North East Health Protection Team, Public Health England Centre North East
Sharon Webb	Sharon Webb Programme Manager - Infectious Diseases in Pregnancy Screening (IDPS), NHS Screening Programmes, Public Health England (Midwife)

2. Organisational authorisations

The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

NHS ENGLAND MIDLANDS AND EAST (CENTRAL MIDLANDS) authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisations and/or services
General medical practices from which NHS England Midlands and East (Central Midlands) commissions immunisation services
Limitations to authorisation

Organisational approval (legal requirement)			
Role	**Name**	**Sign**	**Date**
Medical Director, NHS England Midlands and East (Central Midlands)	**Dr Aly Rashid**		**02.08.17**

Additional signatories according to locally agreed policy			
Role	**Name**	**Sign**	**Date**

Local enquiries regarding the use of this PGD may be directed to:

For **Bedfordshire, Hertfordshire, Luton and Milton Keynes** - england.immsqa@nhs.net - the (Central Midlands) South public health/screening and immunisation team

For **Leicestershire, Lincolnshire and Northamptonshire** – england.llimms@nhs.net - the (Central Midlands) North and Central public health/screening and immunisation team..

Section 7 provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

3. Characteristics of staff

Qualifications and professional registration	Registered professional with one of the following bodies: • nurses currently registered with the Nursing and Midwifery Council (NMC) • paramedics currently registered with the Health and Care Professions Council (HCPC)
Additional requirements	Additionally practitioners: • must be authorised by name as an approved practitioner under the current terms of this Patient Group Direction before working to it • must have undertaken appropriate training for working under PGDs for supply/administration of medicines • must be competent in the use of PGDs (see NICE Competency framework for health professionals using patient group directions) • must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease ("The Green Book"), and national and local immunisation programmes • must have undertaken training appropriate to this PGD as required by local policy and in line with the National Minimum Standards for Immunisation Training (2005) • must be competent to undertake immunisation and to discuss issues related to immunisation • must be competent in the handling and storage of vaccines, and management of the "cold chain" • must be competent in the recognition and management of anaphylaxis • must have access to the Patient Group Direction and associated online resources • should fulfil any additional requirements defined by local policy **THE INDIVIDUAL PRACTITIONER MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE WORKING ACCORDING TO IT.**
Continued training requirements	Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD). Practitioners should be constantly alert to any subsequent recommendations from Public Health England and/or NHS England and other sources of medicines information. Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD.

4. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	Indicated for the active immunisation of individuals from 6 weeks (routinely 8 weeks) to under 10 years of age for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b and hepatitis B in accordance with the national immunisation programme and recommendations given in Chapter 15, Chapter 16, Chapter 18, Chapter 24, Chapter 26, and Chapter 30 of Immunisation Against Infectious Disease: "The Green Book".
Criteria for inclusion	Individuals from 6 weeks to under 10 years of age who: • require a primary course of immunisation against diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b and hepatitis B (including those who do not have a complete or reliable vaccination history, see Special considerations / additional information section) • have a tetanus prone injury and primary immunisation is considered incomplete or immunisation status is not known or uncertain (see "The Green Book" Chapter 30) Note: DTaP/IPV/Hib/HepB should be routinely used for the primary immunisation of infants attaining the age of 8 weeks following the introduction of DTaP/IPV/Hib/HepB into the national programme (ie infants born on or after 1 August 2017). Primary vaccination of older individuals (born before 1 August 2017) should be completed with DTaP/IPV/Hib so long as supplies remain available.
Criteria for exclusion[2]	Individuals for whom no valid consent has been received. Individuals who: • are less than 6 weeks of age • are aged 10 years and over • have had a confirmed anaphylactic reaction to a previous dose of diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b or hepatitis B containing vaccine, including any conjugate vaccines where diphtheria or tetanus toxoid is used in the conjugate • have had a confirmed anaphylactic reaction to any component of the vaccine or residual products from manufacture, including formaldehyde, neomycin and polymyxin (see SPC) • are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation)
Cautions including any relevant action to be taken Continued over page	The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the preventable infection, and vaccination should be promptly given once the diagnosis and/or the expected course of the condition becomes clear. If a child has experienced encephalopathy or encephalitis within seven days of immunisation, it is unlikely that these conditions will

[2] Exclusion under this Patient Group Direction does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required

Cautions including any relevant action to be taken (continued)	have been caused by the vaccine and they should be investigated by a specialist. If a cause is identified or the child recovered within seven days, immunisation should proceed as recommended. In children where no underlying cause was found and the child did not recover completely within seven days, immunisation should be deferred until the condition has stabilized or the expected course of the condition becomes clear. If a seizure associated with a fever occurred within 72 hours of a previous immunisation with pertussis containing vaccine, immunisation should continue as recommended if a cause is identified or the child recovers within 24 hours. However, if no underlying cause has been found and the child did not recover completely within 24 hours, further immunisation should be deferred until the condition is stable. The immunogenicity of the vaccine could be reduced in immunosuppressed subjects, however vaccination is still recommended. Premature infants should be vaccinated in accordance with the national routine immunisation schedule according to their chronological age. Very premature infants (born ≤28 weeks of gestation) who are in hospital should have respiratory monitoring for 48-72 hrs when given their first immunisation, particularly those with a previous history of respiratory immaturity. If the child has apnoea, bradycardia or desaturations after the first immunisation, the second immunisation should also be given in hospital, with respiratory monitoring for 48-72 hrs.
Action to be taken if the patient is excluded	If aged less than 6 weeks advise to return for routine immunisation when the child is 8 weeks of age or over and give an appropriate appointment. Immunisation can be administered to infants from 6 weeks of age if required eg if travelling to an endemic country or at increased risk of hepatitis B virus and dose of HepB vaccine is due. If aged 10 years or over assess for immunisation with Td/IPV as appropriate. In case of postponement due to acute severe febrile illness, advise when the individual can be vaccinated and ensure another appointment is arranged. Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual's clinician when a vaccine is indicated outside the remit of this PGD rather than delay immunisation. The risk to the individual of not being immunised must be taken into account. Document the reason for exclusion and any action taken in the individual's clinical records. In a GP practice setting, inform or refer to the GP or a prescriber as appropriate.

Continued over Page

Action to be taken if the patient or carer declines treatment	Informed consent, from the individual or a person legally able to act on the person's behalf, must be obtained for each administration. Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications of disease. Document advice given and the decision reached. In a GP practice setting, inform or refer to the GP as appropriate.
Arrangements for referral for medical advice	As per local policy

Continued over page

5. Description of treatment

Name, strength & formulation of drug	Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated), *Haemophilus influenzae* type b (conjugate) and hepatitis B (rDNA) vaccine (adsorbed), DTaP/IPV/Hib/HepB, eg: • Infanrix®-hexa, powder (Hib) in vial and suspension (DTaP/IPV/HepB) for suspension for injection in a pre-filled syringe or vial
Legal category	Prescription only medicine (POM)
Black triangle▼	No
Off-label use	Administration of Infanrix®-hexa (DTaP/IPV/Hib/HepB) to individuals born before 24 weeks of gestational age or to individuals who are over 36 months of age is off-label but is indicated until 10 years of age under this PGD in accordance with PHE recommendations for the vaccination of individuals with uncertain or incomplete immunisation status and the relevant chapters of "The Green Book". Administration of DTaP/IPV/Hib/HepB to individuals who experienced an encephalopathy of unknown cause occurring within 7 days following previous vaccination with pertussis containing vaccine is off-label. Individuals may be vaccinated under this PGD once the condition has stabilized or the expected course of the condition becomes clear (see Cautions), in line with the recommendations in the associated chapters of "The Green Book". Administration by deep subcutaneous injection to patients with a bleeding disorder is off-label administration in line with advice in Chapter 4 of "The Green Book". Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/patient/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence.
Route / method of administration	DTaP/IPV/Hib/HepB is presented in two parts, as DTaP/IPV/HepB suspension for injection and Hib powder, which must be reconstituted in accordance with the manufacturers' instructions prior to administration. Administer by intramuscular injection, preferably into the anterolateral aspect of the thigh in infants under one year of age. The deltoid region of the upper arm may be used in individuals over one year of age When administering at the same time as other vaccines care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records. For individuals with a bleeding disorder, vaccines normally given by an intramuscular route should be given by deep subcutaneous injection to reduce the risk of bleeding (see "The Green Book" Chapter 4). The vaccine's normal appearance is a white, slightly milky liquid,

Continued over page

Route / method of administration (continued)	which may sediment during storage. Shake the DTaP/IPV/HepB suspension for injection well to uniformly distribute the suspension prior to reconstitution of the vial containing the powder (Hib) and before administering the vaccine. The vaccine should be inspected prior to and after reconstitution and should not be used if discoloured or foreign particles are present. The reconstituted vaccine appears as a slightly more cloudy suspension than the liquid component alone. The SPC provides further guidance on administration and is available from the electronic Medicines Compendium website: www.medicines.org.uk
Dose and frequency of administration continued over page	Single 0.5ml dose per administration **Routine Childhood Immunisation Schedule** The national recommendation for infants is for a three dose primary course of DTaP/IPV/Hib/HepB to be administered at 4 week intervals* routinely starting at 8 weeks of age (and no earlier than 6 weeks* of age). DTaP/IPV/Hib/HepB 0.5ml should ideally be given at the: • first primary immunisation visit (usually at age 8 weeks) • second primary immunisation visit (usually at age 12 weeks) • third primary immunisation visit (usually at age 16 weeks) *Note: immunisation may be brought forward to commence no earlier than 6 weeks of age, and an interval of not less than 3 weeks (for one dose only), when required eg due to impending travel to an endemic country. **Vaccination of individuals with incomplete immunisation status** When primary vaccination has been delayed the individual should be immunised at the earliest opportunity. If the primary course is interrupted it should be resumed but not repeated, allowing an interval of 4 weeks between remaining doses. It is preferable that the same DTaP-containing vaccine be used for all three doses of the primary course (see the pentavalent vaccine DTaP/IPV/Hib PGD if applicable). If a course was commenced with pentavalent vaccine (DTaP/IPV/Hib) but it is no longer or not readily available, give the hexavalent vaccine DTaP/IPV/Hib/HepB. DTaP/IPV/Hib/HepB can be given to eligible individuals until 10 years of age in accordance with the vaccination of individuals with uncertain or incomplete immunisation status guidance. **Management of tetanus prone wound** Individuals with incomplete or uncertain history of tetanus immunisation should be vaccinated in accordance with the recommendations in the "The Green Book" Chapter 30 Table 30.1. Individuals may also require human tetanus immunoglobulin (see "The Green Book" Chapter 30). This PGD does not cover the administration of immunoglobulin. **Immunisation of infants at risk of hepatitis B** Infants born to hepatitis B infected mothers should receive monovalent hepatitis B (HepB) vaccine (see HepB PGD) at birth and

Dose and frequency of administration (continued)	4 weeks of age and then three doses of DTaP/IPV/Hib/HepB vaccine at 8, 12 and 16 weeks of age. They should receive a booster dose of monovalent HepB vaccine (see HepB PGD) at 12 months of age, at which time they should also have a blood test to check for hepatitis B infection. Where such infants have received doses of monovalent hepatitis B vaccine scheduled for 0 and 4 weeks late, but before 6 weeks of age, routine primary immunisations should still continue to be scheduled at 8 weeks of age, irrespective of the timing of the late monovalent hepatitis B vaccine dose. This is necessary in order not to delay protection against the other infections. If an infant born to a hepatitis B infected mother attends after the age of 6 weeks for their first or second dose of hepatitis B vaccine, DTaP/IPV/Hib/HepB should be administered along with the primary immunisation series (ie MenB, rotavirus and PCV13) with subsequent immunisation visits scheduled at 4 week intervals. In this situation it is very important that the child is tested, at 12 months of age, to check whether they were infected early in life as they missed an early dose of HepB vaccine.
Duration of treatment	The primary course usually consists of three doses with an interval of one month between each dose. Other diphtheria, tetanus, pertussis and polio containing vaccines are routinely recommended for subsequent boosters to complete immunisation in accordance with national recommendations.
Quantity to be supplied / administered	Single 0.5ml dose per administration.
Supplies	Centrally purchased vaccines for the national immunisation programme for the NHS can only be ordered via ImmForm. Vaccines for use for the national immunisation programme are provided free of charge. Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see protocol for ordering storage and handling of vaccines and Green Book Chapter 3).
Storage continued over page	Store at +2°C to +8°C. Store in original packaging in order to protect from light. Do not freeze. Stability data indicate that the vaccine components are stable at temperatures up to 25°C for 72 hours. These data are intended to guide healthcare professionals in case of temporary inadvertent temperature excursion only. This PGD may be used to administer vaccine that has not exceeded the stability data parameters. Breaches in the cold chain should be reported to the Screening and Immunisation Team in line with local arrangements. Vaccine that has exceeded 25°C or been exposed to temperatures above 8°C for more than 72 hours should be quarantined and further advice should be sought from the local Screening and Immunisation or Health Protection Team. After reconstitution vaccine should be used immediately. However, stability has been demonstrated for 8 hours at 21°C after

Storage (continued)	reconstitution. In the event of an unanticipated delay in administration, so long as these parameters have not been exceeded the vaccine may be used.
Disposal	Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of at the end of a session by sealing in a UN-approved puncture-resistant 'sharps' box, according to local authority regulations and guidance in the technical memorandum 07-01: Safe management of healthcare waste (Department of Health, 2013).
Drug interactions	Immunological response may be diminished in those receiving immunosuppressive treatment. This is not a reason to withhold vaccination but the patient/parent/carer should be advised. May be given at the same time as other vaccines (see Identification and management of adverse reactions). A detailed list of interactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk
Identification & management of adverse reactions	When hepatitis B vaccine is added to DTaP/IPV/Hib vaccine the frequency and type of adverse reactions experienced remain similar. When PCV13 is given alongside infant DTaP-containing combination vaccines, such as DTaP/IPV/Hib/HepB, the rate of fever is higher than when either vaccine is administered alone. In the current UK schedule, infants receive these vaccines alongside 4CMenB vaccination at 8 and 16 weeks of age. The routine recommendation to offer prophylactic paracetamol with the infant doses of 4CMenB is expected to also reduce the rate of fever attributed to co-administration of PCV13 and DTaP/IPV/Hib/HepB (see the information about MenB vaccine and paracetamol and the "What to expect after vaccinations" leaflet on the PHE Immunisation webpage for more information). Local reactions following vaccination are very common ie pain, swelling or redness at the injection site. A small painless nodule may form at the injection site. Other common adverse reactions include fever, abnormal crying, irritability, restlessness, appetite loss, fatigue, diarrhoea, vomiting and nervousness. Hypersensitivity reactions, such as bronchospasm, angioedema, urticaria, and anaphylaxis can occur but are very rare. A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: www.medicines.org.uk
Reporting procedure of adverse reactions	Healthcare professionals and patients/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: http://yellowcard.mhra.gov.uk Any adverse reaction to a vaccine should be documented in the individual's record and the individual's GP should be informed.

Written information to be given to patient or carer	Offer marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine. Immunisation promotional material may be provided as appropriate: • A guide to immunisations for babies up to 13 months of age • A quick guide to childhood immunisation for the parents of premature babies • What to expect after vaccinations • Using paracetamol to prevent and treat fever after MenB vaccination Available from: www.gov.uk/government/collections/immunisation
Patient advice / follow up treatment	Inform the individual/parent/carer of possible side effects and their management. Advise the parent about administering prophylactic paracetamol with routine immunisations scheduled at 8 weeks and 16 weeks of age when DTaP/IPV/Hib/HepB is co-administered with MenB and PCV13 vaccine (see Identification & management of adverse reactions). The individual/parent/carer should be advised to seek medical advice in the event of an adverse reaction. When administration is postponed advise the individual/carer when to return for vaccination.
Special considerations / additional information continued over page	Ensure there is immediate access to adrenaline (epinephrine) 1 in 1000 injection and access to a telephone at the time of vaccination. Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered. Wherever possible, the same DTaP-containing vaccine product should be used for all three doses of the primary vaccine course. If this is not possible, whichever primary vaccine is available (Pediacel® or Infanrix®-IPV+Hib) should be used. Vaccination should not be delayed because the vaccine used for previous doses is unavailable or not known. Children coming to the UK who have a history of completing immunisation in their country of origin may not have been offered protection against all the antigens currently used in the UK. They may not have received Hib-containing vaccines in their country of origin, see: http://apps.who.int/immunization_monitoring/globalsummary/ Children coming from developing countries, from areas of conflict, or from hard-to-reach population groups may not have been fully immunised. Where there is no reliable history of previous immunisation, it should be assumed that individuals are unimmunised and the full UK recommendations should be followed. Un- or incompletely immunised children require one dose of Hib over the age of one year. It does not matter if the child receives additional Hib at subsequent appointments if the DTaP/IPV/Hib/HepB vaccine is given. If a person has received vaccination for a tetanus-prone wound with the same vaccine as due for routine immunisation and it was administered at an appropriate interval then the routine immunisation

Special considerations / additional information (continued)	is not required, refer to advice in "The Green Book" Chapter 30. Tetanus vaccine given at the time of a tetanus-prone injury may not boost immunity early enough to give additional protection within the incubation period of tetanus. Therefore, tetanus vaccine is not considered adequate for treating a tetanus-prone wound. However, this provides an opportunity to ensure that the individual is protected against future exposure. Individuals may also require human tetanus immunoglobulin which is not covered by this PGD (see "The Green Book" Chapter 30).
Records	Record: • that valid informed consent was given • name of individual, address, date of birth and GP with whom the individual is registered • name of immuniser • name and brand of vaccine • date of administration • dose, form and route of administration of vaccine • quantity administered • batch number and expiry date • anatomical site of vaccination • advice given, including advice given if excluded or declines immunisation • details of any adverse drug reactions and actions taken • supplied via Patient Group Direction (PGD) Records should be signed and dated (or a password controlled immuniser's record on e-records). All records should be clear, legible and contemporaneous. This information should be recorded in the individual's GP record. Where vaccine is administered outside the GP setting appropriate health records should be kept and the individual's GP informed. The local Child Health Information Systems team (Child Health Records Department) must be notified using the appropriate documentation/pathway when vaccine is administered to individuals under 19 years of age. A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.

6. Key references

Key references	DTaP/IPV/Hib/HepB vaccine

DTaP/IPV/Hib/HepB vaccine

- Immunisation Against Infectious Disease: The Green Book Chapter 15, Chapter 16, Chapter 26 and Chapter 30 last updated 19 April 2013; Chapter 24, last updated 7 April 2016; and Chapter 18, last updated 26 February 2016 (and subsequent draft update) https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
- Summary of Product Characteristic for Infanrix®-hexa, GlaxoSmithKline. Last updated on eMC 17 May 2017. https://www.medicines.org.uk/emc/medicine/33313
- NHS public health functions agreement 2017-18. Service specification No.4. Immunisation against diphtheria, tetanus, poliomyelitis, pertussis and Hib programme. April 2017. https://www.england.nhs.uk/wp-content/uploads/2017/04/service-spec-04.pdf
- The hexavalent DTaP/IPV/Hib/HepB combination vaccine information for healthcare practitioners https://www.gov.uk/government/publications/hexavalent-combination-vaccine-programme-guidance
- Vaccination of individuals with uncertain or incomplete immunisation status. Public Health England. https://www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status

General

- PHE Immunisation Collection https://www.gov.uk/government/collections/immunisation
- British National Formulary (BNF) and British National Formulary for Children (BNF-C) www.BNF.org http://www.evidence.nhs.uk/formulary/bnf/current
- National Minimum Standards for Immunisation Training (2005) https://www.gov.uk/government/publications/immunisation-training-national-minimum-standards
- NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published March 2017. https://www.nice.org.uk/guidance/mpg2
- NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. January 2014. https://www.nice.org.uk/guidance/mpg2/resources
- Immunisation knowledge and skills competence assessment tool. Royal College of Nursing (RCN) 2015. https://www.rcn.org.uk/professional-development/publications/pub-005336
- Protocol for ordering storage and handling of vaccines. April 2014. https://www.gov.uk/government/publications/protocol-for-ordering-storing-and-handling-vaccines
- Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Department of Health 20 March 2013 https://www.gov.uk/government/publications/guidance-on-the-safe-management-of-healthcare-waste

7. Practitioner authorisation sheet

DTaP/IPV/Hib/HepB PGD v01.00 Valid from: 12/09/2017 Expiry: 31/08/2019

Before signing this PGD, check that the document has had the necessary authorisations in section two. Without these, this PGD is not lawfully valid.

Practitioner

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of _____ (insert name of practice) for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.